The trailing P/E of 87x masks a forward P/E of 14.3x. Skyrizi and Rinvoq are on pace to exceed peak Humira revenue by 2027, and the market has not fully priced in the replacement math.
AbbVie's trailing P/E of 87.6x is a mirage. One-time charges related to acquisitions and restructuring have depressed trailing earnings to $2.38 per share, a figure that wildly understates the company's ongoing earnings power. The forward P/E of 14.3x tells the real story: AbbVie is expected to earn approximately $14.50 per share over the next twelve months, which prices the stock at a meaningful discount to both the S&P 500 and the large-cap pharma sector.
At $368.6 billion market capitalisation, with $17.8 billion in free cash flow and a 3.2% dividend yield, AbbVie offers a rare combination: a defensive pharma compounder trading below its intrinsic value because the market is still pricing in Humira erosion fears that the financial data has already begun to resolve.
The thesis is simple: AbbVie's post-Humira product portfolio, led by Skyrizi and Rinvoq, will generate more revenue by 2027 than Humira did at its peak. The replacement maths work. The market has not yet fully priced in the magnitude of that revenue recovery.
Humira generated approximately $21 billion in peak annual revenue in 2022. Biosimilar competition, which began in earnest in the US in 2023, has eroded that figure by an estimated 50-60%. The revenue hole is real. But AbbVie's immunology replacement portfolio is filling it faster than most analysts expected.
Skyrizi (risankizumab) grew to approximately $12-13 billion in annual revenue in fiscal 2025, up from $7.5 billion in 2024. Rinvoq (upadacitinib) added roughly $6-7 billion. Together, these two products generated approximately $19-20 billion in fiscal 2025 revenue, nearly matching peak Humira revenue. By 2027, combined Skyrizi and Rinvoq revenue is projected to exceed $27 billion, surpassing Humira's all-time peak by over 25%.
The margin profile of the replacement portfolio is actually superior to Humira's late-stage economics. Humira faced rising rebate pressure and formulary competition in its final years as the branded product. Skyrizi and Rinvoq, with fresher patent protection extending into the 2030s, enjoy higher net pricing and lower rebate exposure. The gross margin on the replacement portfolio is estimated at 85-90%, versus Humira's late-stage net margin of 75-80%.
The closest historical parallel is Pfizer's Lipitor-to-Eliquis transition. Pfizer's stock languished for years during the patent cliff, then re-rated sharply as the replacement portfolio proved its earnings power. AbbVie is approximately two years into the same re-rating cycle.
TickerXray Report
Get the complete AbbVie report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
AbbVie generated $17.8 billion in free cash flow in fiscal 2025, a slight decline from the $22-24 billion peak during Humira's final years but still an enormous cash generation engine. The free cash flow funds a $7.5 billion annual dividend commitment (yielding 3.2%), significant share repurchases, and ongoing business development.
The Allergan acquisition, completed in 2020 for $63 billion, has been criticised for the debt load it imposed. That criticism was valid three years ago. Today, AbbVie has reduced acquisition-related debt by over $25 billion through aggressive repayment funded by operating cash flow. The balance sheet is approaching pre-Allergan leverage ratios, which opens the door for additional strategic M&A.
AbbVie's Botox franchise, acquired through Allergan, generates approximately $5 billion in annual revenue with high margins and remarkable demand stability. The aesthetics and neuroscience businesses diversify AbbVie beyond immunology, reducing the single-product concentration risk that defined the Humira era. At 14.3x forward earnings, the market assigns effectively zero value to this diversification.
With a beta of 0.36, AbbVie is among the lowest-volatility large-cap stocks in the market. In a macro environment characterised by tariff uncertainty, potential recession, and elevated equity market volatility, that defensive profile commands a premium. Yet AbbVie trades at a discount to the market on a forward P/E basis.
The 50-day moving average at $219.61 and 200-day at $217.11 are nearly overlapping, with the stock trading just above both. This flat moving average configuration typically resolves with a directional move. Given the fundamental trajectory (accelerating revenue, expanding margins, declining debt), the probabilities favour an upside breakout.
The analyst consensus target of $249 implies roughly 20% upside, with the most bullish estimates reaching $275-280. For a stock with a 0.36 beta and a 3.2% dividend yield, that risk-reward profile is compelling. The total return potential (20% capital appreciation plus 3.2% dividend yield) significantly exceeds what most defensive assets offer in the current environment.
The 52-week range of $163 to $239 shows AbbVie has already rallied substantially from its lows, but the rally has been driven by improving fundamentals rather than multiple expansion. At 14.3x forward earnings, the multiple is actually compressed relative to where AbbVie traded in 2021-2022 when Humira was still at peak revenue. As the market gains confidence in the Skyrizi-Rinvoq revenue trajectory, multiple expansion from 14x to 17-18x forward earnings is the primary catalyst.
At 14.3x forward earnings with a 3.2% dividend yield, AbbVie is mispriced for the quality and growth trajectory of its post-Humira portfolio. Skyrizi and Rinvoq are on track to exceed peak Humira revenue by 2027. Operating margins are expanding. Free cash flow funds both the dividend and accelerated debt reduction. The Botox franchise adds diversification that the valuation ignores.
Our fair value estimate is $260-275, representing 17-18x forward earnings, which would bring AbbVie in line with large-cap pharma peers like Eli Lilly and Merck on a growth-adjusted basis. With the 3.2% dividend yield included, total return potential exceeds 25% over twelve months.
We are buyers at current levels. The Humira cliff was the risk; the replacement portfolio is the reward. The market is still pricing in the risk while the reward has already begun to materialise.
Full forensic analysis of AbbVie
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
Our 2024 piece argued the market was under-pricing the post-Humira ramp. Eighteen months later, the data supports the original view and extends the upside.
The consensus frames AbbVie as a post-Humira recovery story with a 14x forward P/E and a 3.2% dividend. The debt stack, the net income trajectory, and the biosimilar trajectory tell a more cautious story.
AbbVie's dividend yield of 3.1% and aggressive acquisition strategy tell a story the income statement alone can't — management is betting the Humira cliff was already priced in and is deploying capital for the next growth cycle.